New Delhi, 25 February (IANS). New research has shown that GLP-1 receptor can now be used in the treatment of Opioid Use Disorder (OUD).
A three -week study was conducted at the Caren Treatment Center in Pennsylvania, USA, which included 20 patients. The study tested the drug named Novo Nordisk’s Saxnda (Liraglutide). It was observed how effective this drug is in the treatment of OUD. This drug is a GLP-1 receptor agonist.
The study found that Saxnda is not only effective as existing treatments, but also saw a decrease of 40% in the desire to take opioids. This information was given by the data and analysis company called Globaldata.
GLP-1 receptor-based drugs were first made to treat diabetes. They increase insulin in the body and control glucagon, causing blood sugar to remain balanced.
Pharma analyst Jose Opdenkar in Globaldeta said that GLP-1 receptor is also in the part of the brain, which is associated with desire and reward. Drug -making companies are interested in it as they want to get rid of drug addiction by using their medicines.
Initial investigations showed that GLP-1 RA is a new and promising way to treat OUD. Right now, the methods of treatment have not changed much and the treatment of OUD is currently dependent on the old methods.
According to GlobalData reports, 6 of the 7 new drugs being developed for OUD are non-opioid based. However, solid data related to the effectiveness of many of these drugs is not yet available.
Therefore, even though there is some non -opioid pipeline, but very effective non -opioid drugs are still lacking, and this is a big chance
Apart from OUD, research is also being done to treat other diseases on GLP-1 receptor-based drugs, such as problems related to Alzheimer’s and memory, Parkinson’s disease, alcohol addiction, nervous system problems and intracranial hypertension.
Scientists believe that GLP-1 receptor-based new drugs can lead to great progress in the field of neurology.
-IANS
AS/
